Can cost-effectiveness principles be ignored in urgent times?

J Comp Eff Res. 2022 Jan;11(1):7-9. doi: 10.2217/cer-2021-0211. Epub 2021 Oct 20.

Authors

Zoltán Kaló^{1

2}, Bertalan Németh², Antal Zemplényi^{2

3}

Affiliations

¹ Center for Health Technology Assessment, Semmelweis University, Üllői Street 25, Budapest, 1091, Hungary.
² Syreon Research Institute, Mexikói Street 65/A, Budapest, 1142, Hungary.
³ Division of Pharmacoeconomics, Faculty of Pharmacy, University of Pécs, Rákóczi Street 2, Pécs, 7623, Hungary.

No abstract available

Keywords: COVID-19; coverage with evidence development; evidence-based decision-making; health economics; real-world data.

Publication types

Editorial

MeSH terms

Cost-Benefit Analysis
Decision Making*
Humans
Technology Assessment, Biomedical*